1953-04-4 | Galanthamine hydrobromide

Packsize	Purity	Availability	Price	Discounted Price
25mg	98%	in stock	$47.00	$33.00
50mg	98%	in stock	$87.00	$61.00
100mg	98%	in stock	$102.00	$72.00
250mg	98%	in stock	$248.00	$174.00
1g	98%	in stock	$561.00	$393.00
5g	98%	in stock	$2,659.00	$1,862.00

Description

• Catalog Number: AB46198
• Chemical Name: Galanthamine hydrobromide
• CAS Number: 1953-04-4
• Molecular Formula: C17H22BrNO3
• Molecular Weight: 368.2655
• MDL Number: MFCD00067672
• SMILES: COc1ccc2c3c1O[C@@H]1[C@@]3(CCN(C2)C)C=C[C@@H](C1)O.Br

Computed Properties

• Complexity: 440
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 3
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 1

Upstream Synthesis Route

The molecule (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide, known for its unique structure, serves as a valuable reagent in chemical synthesis. Its strategic placement of functional groups and stereochemistry make it a versatile building block in the construction of complex organic compounds and pharmaceutical intermediates. Specifically, this compound can be utilized in the synthesis of heterocyclic structures, drug candidates, and natural product analogs due to its potential for forming key bonds and scaffolds essential for target molecules. As a result, this compound plays a crucial role in the advancement of synthetic methodologies and the discovery of novel chemical entities within the field of organic chemistry.

Literature

• Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action.

  Chemico-biological interactions 20171101

• Zebrafish biosensor for toxicant induced muscle hyperactivity.

  Scientific reports 20160101

• Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice.

  Neuroscience 20150709

• Cloning and characterization of a norbelladine 4'-O-methyltransferase involved in the biosynthesis of the Alzheimer's drug galanthamine in Narcissus sp. aff. pseudonarcissus.

  PloS one 20140101

• Simultaneous quantification of Amaryllidaceae alkaloids from Zephyranthes grandiflora by UPLC-DAD/ESI-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20121201

• Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.

  Bioorganic & medicinal chemistry 20121115

• Food-drug interactions: effect of capsaicin on the pharmacokinetics of galantamine in rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20121101

• Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system.

  International journal of pharmaceutics 20121015

• Quantification of galantamine in human plasma by validated liquid chromatography-tandem mass spectrometry using glimepride as an internal standard: application to bioavailability studies in 32 healthy Korean subjects.

  Journal of chromatographic science 20121001

• Mapping of the interaction sites of galanthamine: a quantitative analysis through pairwise potentials and quantum chemistry.

  Journal of computer-aided molecular design 20121001

• Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120901

• Effects of fungicides on galanthamine and metabolite profiles in Narcissus bulbs.

  Plant physiology and biochemistry : PPB 20120901

• High-performance liquid chromatography with fast-scanning fluorescence detection and multivariate curve resolution for the efficient determination of galantamine and its main metabolites in serum.

  Analytica chimica acta 20120831

• Acetylcholinesterase-inhibiting activity of salicylanilide N-alkylcarbamates and their molecular docking.

  Molecules (Basel, Switzerland) 20120824

• Effect on cognition of galanthamine administered for neuromuscular block reversal in octogenarians undergoing cataract surgery.

  Anaesthesiology intensive therapy 20120808

• Production of galanthamine by Leucojum aestivum shoots grown in different bioreactor systems.

  Applied biochemistry and biotechnology 20120801

• GC-MS of amaryllidaceous galanthamine-type alkaloids.

  Journal of mass spectrometry : JMS 20120801

• Two galantamine titration regimens in patients switched from donepezil.

  Acta neurologica Scandinavica 20120701

• 8-[2-(2-Pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid and its diastereomers improve age-related cognitive deterioration.

  Lipids 20120701

• Galantamine administration in chronic post-stroke aphasia.

  Journal of neurology, neurosurgery, and psychiatry 20120701

• Galantamine effect on tularemia pathogenesis in a BALB/c mouse model.

  Iranian biomedical journal 20120701

• Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study.

  European archives of psychiatry and clinical neuroscience 20120601

• Galantamine-based hybrid molecules with acetylcholinesterase, butyrylcholinesterase and γ-secretase inhibition activities.

  Current Alzheimer research 20120601

• Galantamine attenuates the heroin seeking behaviors induced by cues after prolonged withdrawal in rats.

  Neuropharmacology 20120601

• Total synthesis of (-)-galanthamine and (-)-lycoramine via catalytic asymmetric hydrogenation and intramolecular reductive Heck cyclization.

  Organic letters 20120601

• Mixed-effect circadian rhythm model for human erythrocyte acetylcholinesterase activity--application to the proof of concept of cholinesterase inhibition by acorn extract in healthy subjects with galantamine as positive control.

  European journal of clinical pharmacology 20120501

• Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20120501

• Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?

  American journal of Alzheimer's disease and other dementias 20120501

• Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.

  Drugs 20120416

• Galantamine (Reminyl) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current.

  European journal of pharmacology 20120415

• New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

  British journal of clinical pharmacology 20120401

• Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.

  Psychopharmacology 20120401

• Drugs for Alzheimer's disease.

  British journal of clinical pharmacology 20120401

• Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.

  The Annals of pharmacotherapy 20120401

• Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

  Cold Spring Harbor perspectives in medicine 20120301

• Galantamine elicits neuroprotection by inhibiting iNOS, NADPH oxidase and ROS in hippocampal slices stressed with anoxia/reoxygenation.

  Neuropharmacology 20120201

• [Pharmacological profiles of galantamine: the involvement of muscarinic receptor].

  Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 20120201

• Acetylcholinesterase inhibitors for schizophrenia.

  The Cochrane database of systematic reviews 20120118

• Alkaloid patterns in Leucojum aestivum shoot culture cultivated at temporary immersion conditions.

  Journal of plant physiology 20120115

• Effects of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats.

  Current Alzheimer research 20120101

• Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors.

  Journal of Alzheimer's disease : JAD 20120101

• The economic impact of galantamine vs placebo: an analysis based on functional capacity in a Swedish cohort study.

  Journal of medical economics 20120101

• The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

  Health technology assessment (Winchester, England) 20120101

• [New anti-AD drugs--their possibilities and issues].

  Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20120101

• A novel subject synchronization clinical trial design for Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20120101

• A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.

  The journal of nutrition, health & aging 20120101

• Controlled release reservoir mini tablets approach for controlling the drug release of Galantamine Hydrobromide.

  Pharmaceutical development and technology 20120101

• Donepezil, but not galantamine, blocks muscarinic receptor-mediated in vitro and in vivo responses.

  Synapse (New York, N.Y.) 20111201

• Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance.

  Neurotoxicology 20111201

• Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus.

  Neuropharmacology 20111201

• Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram.

  Biochimica et biophysica acta 20111201

• Medicinal plants and dementia therapy: herbal hopes for brain aging?

  CNS neuroscience & therapeutics 20111201

• [Galantamine].

  Nihon rinsho. Japanese journal of clinical medicine 20111201

• Kinetic study of the rearrangement of deuterium-labeled 4'-O-methylnorbelladine in Leucojum aestivum shoot cultures by mass spectrometry. Influence of precursor feeding on amaryllidaceae alkaloid accumulation.

  Journal of natural products 20111128

• Acetylcholinesterase-inhibiting alkaloids from Zephyranthes concolor.

  Molecules (Basel, Switzerland) 20111115

• Galantamine and behavior in Alzheimer disease: analysis of four trials.

  Acta neurologica Scandinavica 20111101

• BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

  European journal of clinical pharmacology 20111101

• Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment.

  Current Alzheimer research 20111101

• Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.

  Hormones and behavior 20111101

• Effective pharmacological management of Alzheimer's disease.

  The American journal of managed care 20111101

• The costs of Alzheimer's disease and the value of effective therapies.

  The American journal of managed care 20111101

• Galantamine rescues lead-impaired synaptic plasticity in rat dentate gyrus.

  Toxicology 20111028

• Structural features and hydrogen-bond properties of galanthamine and codeine: an experimental and theoretical study.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20111004

• Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation.

  Bioorganic & medicinal chemistry letters 20111001

• Pharmacological treatment of Alzheimer disease.

  Canadian journal of psychiatry. Revue canadienne de psychiatrie 20111001

• The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

  Behavioural brain research 20110930

• Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation.

  Hippocampus 20110901

• Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease.

  Pharmacology, biochemistry, and behavior 20110901

• An overview on natural cholinesterase inhibitors--a multi-targeted drug class--and their mass production.

  Mini reviews in medicinal chemistry 20110901

• Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.

  Expert opinion on investigational drugs 20110901

• Effects of cholinesterase inhibitors on postoperative outcomes of older adults with dementia undergoing hip fracture surgery.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20110901

• [Pharmacological and clinical profiles of galantamine (Reminyl(®))].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20110901

• Asymmetric synthesis of bioactive hydrodibenzofuran alkaloids: (-)-lycoramine, (-)-galanthamine, and (+)-lunarine.

  Angewandte Chemie (International ed. in English) 20110822

• Alkaloids from Hippeastrum papilio.

  Molecules (Basel, Switzerland) 20110818

• Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study.

  The American journal of geriatric pharmacotherapy 20110801

• [Newly approved drugs for Alzheimer disease: effectiveness and limitation].

  Brain and nerve = Shinkei kenkyu no shinpo 20110801

• New drugs for Alzheimer's disease in Japan.

  Psychiatry and clinical neurosciences 20110801

• Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population.

  Geriatrics & gerontology international 20110701

• [Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales].

  Psychiatrische Praxis 20110701

• [Prescription differences of dementia drugs in urban and rural areas in Germany].

  Psychiatrische Praxis 20110701

• Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.

  The international journal of neuropsychopharmacology 20110601

• Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat.

  Brain research bulletin 20110530

• Possible role of cholinesterase inhibitors on memory consolidation following hypobaric hypoxia of rats.

  The International journal of neuroscience 20110501

• Effects of galantamine on cocaine use in chronic cocaine users.

  The American journal on addictions 20110501

• Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide.

  Journal of pharmaceutical and biomedical analysis 20110428

• Effect of fertilizers on galanthamine and metabolite profiles in Narcissus bulbs by 1H NMR.

  Journal of agricultural and food chemistry 20110413

• Switching cholinesterase inhibitors in older adults with dementia.

  International psychogeriatrics 20110401

• Metabolic profiling of 3-nitropropionic acid early-stage Huntington's disease rat model using gas chromatography time-of-flight mass spectrometry.

  Journal of proteome research 20110401

• Synthesis of (-)-homogalanthamine from naltrexone.

  The Journal of organic chemistry 20110401

• Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.

  Bioorganic & medicinal chemistry 20110401

• Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndrome.

  American journal of medical genetics. Part A 20110401

• Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.

  Prescrire international 20110401

• Prescribing trends in cognition enhancing drugs in Australia.

  International psychogeriatrics 20110301

• Molecular cloning and characterization of a phenylalanine ammonia-lyase gene (LrPAL) from Lycoris radiata.

  Molecular biology reports 20110301

• Synapse- and subtype-specific modulation of synaptic transmission by nicotinic acetylcholine receptors in the ventrobasal thalamus.

  Neuroscience research 20110301

• Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.

  Drug metabolism and disposition: the biological fate of chemicals 20110301

• Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.

  Current Alzheimer research 20110301

• Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study.

  Journal of neural transmission (Vienna, Austria : 1996) 20110301

• Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability.

  International journal of geriatric psychiatry 20110301

• Development and validation of a GC-MS method for rapid determination of galanthamine in Leucojum aestivum and Narcissus ssp.: a metabolomic approach.

  Talanta 20110215

• Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.

  The Gerontologist 20110201

• Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.

  Schizophrenia research 20110201

• Binding of huperzine A and galanthamine to acetylcholinesterase, based on ONIOM method.

  Nanomedicine : nanotechnology, biology, and medicine 20110201

• Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation.

  British journal of pharmacology 20110201

• Acetylcholinesterase inhibitors partially generalize to nicotine discriminative stimulus effect in rats.

  Behavioural pharmacology 20110201

• Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110201

• Galantamine improves sustained attention in chronic cocaine users.

  Experimental and clinical psychopharmacology 20110201

• Ion mobility spectrometry: a valuable tool for kinetic studies in enzymology.

  Analytica chimica acta 20110124

• Galanthamine and related alkaloids production by Leucojum aestivum L. shoot culture using a temporary immersion technology.

  Applied biochemistry and biotechnology 20110101

• Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.

  Alzheimer disease and associated disorders 20110101

• Respiratory myoclonus, a side effect of galantamine.

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

• Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients.

  Journal of Alzheimer's disease : JAD 20110101

• Alkaloid diversity in Galanthus elwesii and Galanthus nivalis.

  Chemistry & biodiversity 20110101

• Pharmacological aspects of the acetylcholinesterase inhibitor galantamine.

  Journal of pharmacological sciences 20110101

• [Cholinesterase blockers in anesthesiology: a replenishment of former arsenal].

  Anesteziologiia i reanimatologiia 20110101

• Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.

  Journal of Alzheimer's disease : JAD 20110101

• Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice.

  Molecular medicine (Cambridge, Mass.) 20110101

• Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.

  Journal of Alzheimer's disease : JAD 20110101

• [Sleep disorders in patients with dementia in Parkinson's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20110101

• [The application of multichannel electrostimulation and nivalin electrophoresis for the rehabilitative treatment of the patient following plastic surgery in the facial region].

  Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury 20110101

• Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome.

  Scientific reports 20110101

• [The application of electrical stimulation by bipolar pulsed currents and galanthamine electrophoresis for the rehabilitation of patients with diabetes mellitus].

  Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury 20110101

• Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors.

  The Journal of biological chemistry 20101217

• Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain.

  Journal of receptor and signal transduction research 20101201

• Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems.

  The international journal of neuropsychopharmacology 20101101

• Effects of galantamine on β-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells.

  Experimental gerontology 20101101

• Protective effects of galantamine against Abeta-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress.

  Neurochemistry international 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities.

  Bioorganic & medicinal chemistry letters 20101101

• [Beneficial effect of galantamine on sensory information-processing deficits].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20101001

• Effects of cholinergic agonists and antagonists under conditions of spleen denervation in rats with endotoxic shock.

  Bulletin of experimental biology and medicine 20101001

• Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease.

  The American journal of geriatric pharmacotherapy 20101001

• Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20100901

• Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells.

  Journal of pineal research 20100901

• Pretreatment of Guinea pigs with galantamine prevents immediate and delayed effects of soman on inhibitory synaptic transmission in the hippocampus.

  The Journal of pharmacology and experimental therapeutics 20100901

• Current treatments for patients with Alzheimer disease.

  The Journal of the American Osteopathic Association 20100901

• Galantamine inhibits calpain-calcineurin signaling activated by beta-amyloid in human neuroblastoma SH-SY5Y cells.

  Neuroscience letters 20100823

• Predictors of adherence among Alzheimer's disease patients receiving oral therapy.

  Current medical research and opinion 20100801

• Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

  Drugs & aging 20100801

• Determination of galanthamine in Bulbus Lycoridis Radiatae by coupling capillary electrophoresis with end-column electrochemiluminescence detection.

  Journal of separation science 20100801

• Effect of cholinesterase inhibitor galanthamine on circulating tumor necrosis factor alpha in rats with lipopolysaccharide-induced peritonitis.

  Chinese medical journal 20100701

• Spectrofluorimetry in organized media coupled to second-order multivariate calibration for the determination of galantamine in the presence of uncalibrated interferences.

  Talanta 20100630

• Young and older good learners have higher levels of brain nicotinic receptor binding.

  Neurobiology of aging 20100601

• Synthesis of 4-[(diethylamino)methyl]-phenol derivatives as novel cholinesterase inhibitors with selectivity towards butyrylcholinesterase.

  Bioorganic & medicinal chemistry letters 20100601

• Cholinesterase inhibitors ameliorate spatial learning deficits in rats following hypobaric hypoxia.

  Experimental brain research 20100601

• The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease.

  Psychiatria Danubina 20100601

• [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].

  Tijdschrift voor gerontologie en geriatrie 20100601

• Semisynthesis and acetylcholinesterase inhibitory activity of stemofoline alkaloids and analogues.

  Journal of natural products 20100528

• Galantamine inhibits slowly inactivating K+ currents with a dual dose-response relationship in differentiated N1E-115 cells and in CA1 neurones.

  European journal of pharmacology 20100525

• Total synthesis of (+/-)-galanthamine via a C3-selective Stille coupling and IMDA cycloaddition cascade of 3,5-dibromo-2-pyrone.

  Organic letters 20100507

• A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients.

  Current clinical pharmacology 20100501

• Anticholinesterase duration in the Australian veteran population.

  The Australian and New Zealand journal of psychiatry 20100501

• Alternative method of oral dosing for rats.

  Journal of the American Association for Laboratory Animal Science : JAALAS 20100501

• [Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease].

  Neurologia (Barcelona, Spain) 20100501

• Super-short solid silicon microneedles for transdermal drug delivery applications.

  International journal of pharmaceutics 20100415

• Acetylcholinesterase enzyme inhibitory potential of standardized extract of Trigonella foenum graecum L and its constituents.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20100301

• Prescribing of drugs for Alzheimer's disease: a South African database analysis.

  International psychogeriatrics 20100301

• Galantamine for Alzheimer's disease.

  Expert opinion on drug metabolism & toxicology 20100301

• Reversible acetylcholinesterase inhibitory effect of Tabernaemontana divaricata extract on synaptic transmission in rat CA1 hippocampus.

  The Indian journal of medical research 20100301

• The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.

  International journal of geriatric psychiatry 20100201

• Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.

  Progress in neuro-psychopharmacology & biological psychiatry 20100201

• [A negative first-line work-up of Raynaud's phenomenon: And what if it were cancer?].

  Journal des maladies vasculaires 20100201

• Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

  CNS drugs 20100201

• Iron leads to memory impairment that is associated with a decrease in acetylcholinesterase pathways.

  Current neurovascular research 20100201

• Galantamine does not cause aggravated orthostatic hypotension in people with Alzheimer's disease.

  Journal of the American Geriatrics Society 20100201

• Structural and functional neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors.

  Cell death & disease 20100201

• Probing Torpedo californica acetylcholinesterase catalytic gorge with two novel bis-functional galanthamine derivatives.

  Journal of medicinal chemistry 20100128

• Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy.

  Journal of molecular neuroscience : MN 20100101

• The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex.

  Journal of molecular neuroscience : MN 20100101

• Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning.

  Journal of molecular neuroscience : MN 20100101

• Analysis of metabolic variation and galanthamine content in Narcissus bulbs by 1H NMR.

  Phytochemical analysis : PCA 20100101

• Magnetic resonance imaging reveals that galantamine prevents structural brain damage induced by an acute exposure of guinea pigs to soman.

  Neurotoxicology 20100101

• Promotion effect of norgalanthamine, a component of Crinum asiaticum, on hair growth.

  European journal of dermatology : EJD 20100101

• Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.

  European journal of medicinal chemistry 20100101

• Frontotemporal dementia and pharmacologic interventions.

  The Journal of neuropsychiatry and clinical neurosciences 20100101

• Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.

  Clinical interventions in aging 20100101

• Cholinergic sensitivity of the developing bullfrog (Rana catesbeiana) does not explain vulnerability to chronic nicotine exposure.

  Advances in experimental medicine and biology 20100101

• Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.

  Dementia and geriatric cognitive disorders 20100101

• Important groups of alkaloids derived biosynthetically from phenylalanine and tyrosine. Preface.

  The Alkaloids. Chemistry and biology 20100101

• Galanthamine from Galanthus and other Amaryllidaceae--chemistry and biology based on traditional use.

  The Alkaloids. Chemistry and biology 20100101

• Galanthamine production by Leucojum aestivum cultures in vitro.

  The Alkaloids. Chemistry and biology 20100101

• New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies.

  Current pharmaceutical design 20100101

• Cortical oxygen supply during postural hypotension is further decreased in Alzheimer's disease, but unrelated to cholinesterase-inhibitor use.

  Journal of Alzheimer's disease : JAD 20100101

• Alkaloid accumulation in different parts and ages of Lycoris chinensis.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20100101

• Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature.

  BMC psychiatry 20100101

• Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany.

  Journal of medical economics 20100101

• Effect of elevated intra-abdominal pressure on the contractile activity and reactivity of smooth muscle tissue from rat gastrointestinal tract to galantamine and drotaverine (No-Spa).

  Folia medica 20100101

• [Cholinesterase inhibitors for treating dementia. Review].

  Vertex (Buenos Aires, Argentina) 20100101

• Dementia.

  BMJ clinical evidence 20100101

• Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease.

  International psychogeriatrics 20091201

• International price comparisons of Alzheimer's drugs: a way to close the affordability gap.

  International psychogeriatrics 20091201

• Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine.

  The Journal of pharmacology and experimental therapeutics 20091201

• Metabolic profiling of rat brain and cognitive behavioral tasks: potential complementary strategies in preclinical cognition enhancement research.

  Journal of proteome research 20091201

• Comparative effectiveness research: an approach to avoiding 'overgeneralized medicine'.

  Clinical and translational science 20091201

• Concise syntheses of (-)-galanthamine and (+/-)-codeine via intramolecular alkylation of a phenol derivative.

  Journal of the American Chemical Society 20091111

• Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.

  Journal of the American Geriatrics Society 20091101

• Alzheimer's disease: Seeing the signs early.

  Journal of the American Academy of Nurse Practitioners 20091101

• Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer.

  Biochemical and biophysical research communications 20091030

• Effects of galantamine on L-NAME-induced behavioral impairment in Y-maze task in mice.

  Neuroscience letters 20091025

• Galantamine is a novel post-exposure therapeutic against lethal VX challenge.

  Toxicology and applied pharmacology 20091015

• Acetylcholinesterase inhibitors enhance cognitive functions in rats following hypobaric hypoxia.

  Behavioural brain research 20091012

• Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.

  International psychogeriatrics 20091001

• Trospium and cognition in patients with late onset Alzheimer disease.

  The journal of nutrition, health & aging 20091001

• Study of acetylcholinesterase inhibitors using CE with contactless conductivity detection.

  Electrophoresis 20091001

• Case report: combined use of donepezil and galantamine in mixed dementia.

  Journal of the American Geriatrics Society 20091001

• Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation.

  Hippocampus 20090901

• Misplacing objects in mild to moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial.

  Journal of neurology, neurosurgery, and psychiatry 20090901

• Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats.

  Journal of the neurological sciences 20090815

• Cholinesterase inhibitory effects of the extracts and compounds of Maclura pomifera (Rafin.) Schneider.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20090801

• Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease.

  Brain research 20090714

• Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

  Acta pharmacologica Sinica 20090701

• Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids.

  Bioorganic & medicinal chemistry letters 20090615

• Electroencephalographic effects of galantamine in major depressive disorder.

  Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 20090601

• A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder.

  Journal of clinical psychopharmacology 20090601

• Drug-induced sialorrhoea and excessive saliva accumulation.

  Prescrire international 20090601

• Galantamine inhibits beta-amyloid aggregation and cytotoxicity.

  Journal of the neurological sciences 20090515

• Treatment of Alzheimer's disease in the long-term-care setting.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090515

• Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.

  Neuroscience 20090505

• Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.

  International journal of geriatric psychiatry 20090501

• Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study.

  Journal of clinical psychopharmacology 20090401

• Two-dimensional turbulent flow chromatography coupled on-line to liquid chromatography-mass spectrometry for solution-based ligand screening against multiple proteins.

  Journal of chromatography. A 20090320

• Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats.

  Progress in neuro-psychopharmacology & biological psychiatry 20090317

• Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines.

  Translational research : the journal of laboratory and clinical medicine 20090301

• Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation.

  Biological & pharmaceutical bulletin 20090301

• Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models.

  Biological & pharmaceutical bulletin 20090301

• An unusual case of nightmares with galantamine.

  Journal of the American Geriatrics Society 20090301

• Characteristic effects of anti-dementia drugs on rat sleep patterns.

  Journal of pharmacological sciences 20090301

• Bullous pemphigoid precipitated by galantamine hydrobromide.

  Cutis 20090301

• Alkaloid synthesis and accumulation in Leucojum aestivum in vitro cultures.

  Natural product communications 20090301

• Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090301

• Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.

  Neuroreport 20090218

• Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils.

  Brain research 20090213

• Pressurized liquid extraction and anticholinesterase activity-based thin-layer chromatography with bioautography of Amaryllidaceae alkaloids.

  Analytica chimica acta 20090209

• Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors.

  European journal of medicinal chemistry 20090201

• Early postnatal maternal deprivation in rats induces memory deficits in adult life that can be reversed by donepezil and galantamine.

  International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 20090201

• Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.

  Brain : a journal of neurology 20090201

• Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.

  Electrophoresis 20090201

• Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

  Current Alzheimer research 20090201

• Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.

  Journal of the American Geriatrics Society 20090201

• Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons.

  The European journal of neuroscience 20090201

• [Effects of anti-dementia drugs on sleep-wake patterns in sleep-disturbed rats].

  Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 20090201

• Galantamine for dementia in people with Down syndrome.

  The Cochrane database of systematic reviews 20090121

• Analyses of mortality risk in patients with dementia treated with galantamine.

  Acta neurologica Scandinavica 20090101

• Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway.

  Brain, behavior, and immunity 20090101

• A single in vivo application of cholinesterase inhibitors has neuron type-specific effects on nicotinic receptor activity in guinea pig hippocampus.

  The Journal of pharmacology and experimental therapeutics 20090101

• A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease.

  Journal of neurology, neurosurgery, and psychiatry 20090101

• Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.

  Psychopharmacology 20090101

• The effects of galantamine on psychopathology in chronic stable schizophrenia.

  Clinical neuropharmacology 20090101

• [Relation between Pisa syndrome and choline esterase inhibitors in a cohort of Alzheimer's disease patients].

  Presse medicale (Paris, France : 1983) 20090101

• The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease.

  The Lancet. Neurology 20090101

• Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.

  The Lancet. Neurology 20090101

• Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20090101

• Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice.

  British journal of pharmacology 20090101

• Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex.

  Journal of Alzheimer's disease : JAD 20090101

• Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.

  CNS drugs 20090101

• Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network.

  Dementia and geriatric cognitive disorders 20090101

• Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

  Drugs & aging 20090101

• Verbal repetition in people with mild-to-moderate Alzheimer Disease: a descriptive analysis from the VISTA clinical trial.

  Alzheimer disease and associated disorders 20090101

• Synthesis and characterization of new galanthamine derivatives comprising peptide moiety.

  Protein and peptide letters 20090101

• Optimized nutrient medium for galanthamine production in Leucojum aestivum L. in vitro shoot system.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20090101

• Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.

  Drugs & aging 20090101

• [Galantamine (reminyl) in the treatment of severe Alzheimer's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?

  Dementia and geriatric cognitive disorders 20090101

• Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study.

  CNS neuroscience & therapeutics 20090101

• Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.

  Dementia and geriatric cognitive disorders 20090101

• [The use of reminyl (galantamine) in the treatment of probable vascular dementia].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• [The use of galantamine in Alzheimer's disease associated with vascular dementia (according to the study of T. Erkinjuntti group)].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101

• Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease.

  Neuroscience letters 20081219

• Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.

  Neuroscience research 20081201

• Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.

  American journal of Alzheimer's disease and other dementias 20081201

• Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine*.

  Current medical research and opinion 20081201

• Effects of cholinotropic and cytostatic drugs on the development of Arthus reaction.

  Bulletin of experimental biology and medicine 20081201

• Evaluation of galantamine transbuccal absorption by reconstituted human oral epithelium and porcine tissue as buccal mucosa models: part I.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20081101

• Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).

  Neuroscience and behavioral physiology 20081101

• [Bradycardia induced by galantamine].

  Annales francaises d'anesthesie et de reanimation 20081101

• Vesicular acetylcholine transporter (VAChT) in the brain of spontaneously hypertensive rats (SHR): effect of treatment with an acetylcholinesterase inhibitor.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20081101

• Domino double Michael-Claisen cyclizations: a powerful general tool for introducing quaternary stereocenters at C4 of cyclohexane-1,3-diones and total synthesis of diverse families of sterically congested alkaloids.

  The Journal of organic chemistry 20081003

• Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial.

  International psychogeriatrics 20081001

• Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat.

  British journal of pharmacology 20081001

• Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.

  Journal of neural transmission (Vienna, Austria : 1996) 20081001

• Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).

  Journal of psychopharmacology (Oxford, England) 20080901

• Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats.

  The international journal of neuropsychopharmacology 20080901

• An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.

  Cerebrovascular diseases (Basel, Switzerland) 20080901

• Spinal p38 MAP kinase regulates peripheral cholinergic outflow.

  Arthritis and rheumatism 20080901

• [Galantamine].

  Revue de l'infirmiere 20080901

• [Galantamine therapy in dementia associated with CADASIL].

  Revista de neurologia 20080901

• The effect of Galantamine on sleep quality in Thai Alzheimer's disease patients.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20080901

• Drug utilization review of cholinesterase inhibitors in Quebec.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20080901

• PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.

  Neurobiology of aging 20080801

• Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.

  Schizophrenia research 20080801

• The safety and tolerability of galantamine in patients with epilepsy and memory difficulties.

  Epilepsy & behavior : E&B 20080801

• Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia.

  Schizophrenia research 20080801

• A nonlinear mixed effects IVIVC model for multi-release drug delivery systems.

  Journal of pharmacokinetics and pharmacodynamics 20080801

• Extracts and constituents of Leontopodium alpinum enhance cholinergic transmission: brain ACh increasing and memory improving properties.

  Biochemical pharmacology 20080715

• High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.

  Schizophrenia research 20080701

• Roles of accessory subunits in alpha4beta2(*) nicotinic receptors.

  Molecular pharmacology 20080701

• Prevalence of cholinesterase inhibitors in subjects with dementia in Europe.

  Pharmacoepidemiology and drug safety 20080701

• The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study.

  Journal of psychiatric research 20080601

• A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression.

  International journal of geriatric psychiatry 20080601

• Galantamine as an adjunctive treatment in major depression.

  Journal of clinical psychopharmacology 20080601

• Hydrogen-bonding properties of galanthamine: an investigation through crystallographic database observations and computational chemistry.

  Acta crystallographica. Section B, Structural science 20080601

• Galantamine-induced pisa syndrome: memantine as an alternative.

  International journal of geriatric psychiatry 20080601

• Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

  Journal of managed care pharmacy : JMCP 20080601

• Safety and efficacy of galantamine in subjects with mild cognitive impairment.

  Neurology 20080527

• Treatment for MCI: is the evidence sufficient?

  Neurology 20080527

• Dementia medications in palliative care #174.

  Journal of palliative medicine 20080501

• Galantamine improves gait performance in patients with Alzheimer's disease.

  Journal of the American Geriatrics Society 20080501

• [Treatment of Alzheimer's disease: status quo and future considerations].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080501

• Diagnosis and treatment of dementia with Lewy bodies.

  JAAPA : official journal of the American Academy of Physician Assistants 20080501

• AAFP and ACP release guideline on dementia treatment.

  American family physician 20080415

• For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not?

  International psychogeriatrics 20080401

• N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum.

  Bioorganic & medicinal chemistry letters 20080401

• Galantamine and carbon monoxide protect brain microvascular endothelial cells by heme oxygenase-1 induction.

  Biochemical and biophysical research communications 20080314

• Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations.

  Annals of internal medicine 20080304

• Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

  Annals of internal medicine 20080304

• Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

  Annals of internal medicine 20080304

• Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells.

  Neurotoxicology 20080301

• Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.

  Neurobiology of aging 20080201

• Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

  International journal of geriatric psychiatry 20080201

• A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.

  International journal of geriatric psychiatry 20080201

• Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.

  International journal of geriatric psychiatry 20080201

• Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20080201

• Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.

  International journal of geriatric psychiatry 20080201

• Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice.

  Psychopharmacology 20080201

• Prolonged QT interval, syncope, and delirium with galantamine.

  The Annals of pharmacotherapy 20080201

• Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study.

  Journal of Korean medical science 20080201

• Pharmacologic management of Alzheimer disease.

  The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 20080201

• [Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080131

• [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].

  Der Nervenarzt 20080101

• Galantamine for the treatment of cognitive impairments in people with schizophrenia.

  The American journal of psychiatry 20080101

• Galantamine in Alzheimer's disease.

  Expert review of neurotherapeutics 20080101

• Galantamine in frontotemporal dementia and primary progressive aphasia.

  Dementia and geriatric cognitive disorders 20080101

• First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.

  Clinical neuropharmacology 20080101

• Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil.

  Alzheimer disease and associated disorders 20080101

• Analysis of galanthamine-type alkaloids by capillary gas chromatography-mass spectrometry in plants.

  Phytochemical analysis : PCA 20080101

• New rapid validated HPTLC method for the determination of galanthamine in Amaryllidaceae plant extracts.

  Phytochemical analysis : PCA 20080101

• The clinical significance of plasmatic amyloid A{beta}-40 peptide levels in Alzheimer's disease patients treated with galantamine.

  American journal of Alzheimer's disease and other dementias 20080101

• One-week dose titration of extended release galantamine in patients with Alzheimer's disease.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20080101

• Review of issue: studies on veterans, a useful pain scale, and plasma amyloid levels as a predictor of response to medications.

  American journal of Alzheimer's disease and other dementias 20080101

• [Combined use of reminyl (galanthamine) and ovestin (oestradiol) for the treatment of cognitive disorders in women with hypoestrogenic syndrome].

  Eksperimental'naia i klinicheskaia farmakologiia 20080101

• Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

  Clinical interventions in aging 20080101

• Combined models for data from in vitro-in vivo correlation experiments.

  Journal of biopharmaceutical statistics 20080101

• Intranasal administration of acetylcholinesterase inhibitors.

  BMC neuroscience 20080101

• Electrically enhanced and controlled drug delivery through buccal mucosa.

  Acta poloniae pharmaceutica 20080101

• Discontinuing Alzheimer's disease drug therapy: why, when, and how.

  Director (Cincinnati, Ohio) 20080101

• Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy.

  Stroke 20071201

• An update on the pharmacology of galantamine.

  Expert opinion on investigational drugs 20071201

• Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.

  Psychiatry and clinical neurosciences 20071201

• Suzuki-Miyaura and Stille reactions as key steps in the synthesis of diversely functionalized Amaryllidaceae alkaloid analogs bearing a 5,6,7,8-tetrahydrobenzo[c,e]azocine skeleton.

  Combinatorial chemistry & high throughput screening 20071101

• Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20071015

• Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment.

  Neurology 20071009

• Impairments in trace EB conditioning by knife-cut lesions to the fornix in rabbits: reversal by galantamine.

  Neurobiology of learning and memory 20071001

• Evaluation of centrally acting cholinesterase inhibitor exposures in adults.

  The Annals of pharmacotherapy 20071001

• Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.

  Prescrire international 20071001

• Diagnosis and management of vascular cognitive impairment.

  Current atherosclerosis reports 20071001

• [The localization of galanthamine in vegetative organ of Lycoris aurea Herb].

  Fen zi xi bao sheng wu xue bao = Journal of molecular cell biology 20071001

• [Are anti-dementia drugs worthwhile?].

  MMW Fortschritte der Medizin 20070913

• Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.

  International journal of geriatric psychiatry 20070901

• Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.

  Neuropharmacology 20070901

• Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.

  The Lancet. Neurology 20070901

• NICE judgement leaves behind a nasty taste.

  Nursing older people 20070901

• The enantioselective synthesis of (-)-lycoramine with the Birch-Cope sequence.

  The Journal of organic chemistry 20070831

• Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.

  Neurology 20070821

• Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils.

  The Journal of pharmacology and experimental therapeutics 20070801

• Galantamine treatment of vascular dementia: a randomized trial.

  Neurology 20070731

• Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease.

  Magnetic resonance imaging 20070701

• Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors.

  The Journal of pharmacology and experimental therapeutics 20070701

• Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.

  Journal of Alzheimer's disease : JAD 20070701

• High-performance liquid chromatographic method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070615

• Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-alpha-subunit interfaces of heteromeric neuronal nicotinic receptors.

  Journal of molecular biology 20070615

• Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats.

  The international journal of neuropsychopharmacology 20070601

• Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070601

• The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070601

• The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys.

  The Journal of pharmacology and experimental therapeutics 20070601

• Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.

  International psychogeriatrics 20070601

• [Cholinesterase inhibitors and Alzheimer's disease: meta-analysis of the verification of effectiveness, origin and bias of results in published studies].

  Deutsche medizinische Wochenschrift (1946) 20070601

• [Galanthamine versus donepezil in the treatment of Alzheimer's disease].

  Revista de neurologia 20070601

• Synthesis of 6beta-D-glucosyl and 6-nitroxy (-)-galanthamine derivatives as acetylcholinesterase inhibitors.

  Die Pharmazie 20070601

• A rabbit model of Alzheimer's disease: valid at neuropathological, cognitive, and therapeutic levels.

  Journal of Alzheimer's disease : JAD 20070601

• [Acetylcholinesterase inhibitors for dementia--an update].

  MMW Fortschritte der Medizin 20070521

• Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.

  Neurology 20070515

• Stereocontrolled synthesis of (-)-galanthamine.

  Organic letters 20070510

• In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo.

  International journal of pharmaceutics 20070420

• Post-ischemic continuous administration of galantamine attenuates cognitive deficits and hippocampal neurons loss after transient global ischemia in gerbils.

  Neuroscience letters 20070406

• Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.

  Neurology 20070403

• Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors.

  International journal of geriatric psychiatry 20070401

• The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients.

  Journal of clinical psychopharmacology 20070401

• Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil and galantamine.

  Age and ageing 20070301

• A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

  International clinical psychopharmacology 20070301

• A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.

  International journal of clinical practice 20070301

• Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model.

  Neuropharmacology 20070301

• Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.

  Pharmacotherapy 20070301

• Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.

  The Journal of clinical psychiatry 20070301

• Pharmacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers.

  Drug development and industrial pharmacy 20070301

• Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats.

  Neuropharmacology 20070201

• Anti-Alzheimer drugs: life-threatening adverse effects.

  Prescrire international 20070201

• Quantitative determination of galantamine in human plasma by sensitive liquid chromatography-tandem mass spectrometry using loratadine as an internal standard.

  Journal of chromatographic science 20070201

• Nicotinic component of galantamine in the regulation of amyloid precursor protein processing.

  Chemico-biological interactions 20070130

• Changes of cholinesterase activities in the plasma and some tissues following administration of L-carnitine and galanthamine to rats.

  Neuroscience letters 20070116

• Preparation of secolycorines against acetylcholinesterase.

  Bioorganic & medicinal chemistry 20070115

• Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070101

• Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition.

  Synapse (New York, N.Y.) 20070101

• Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials.

  Drugs & aging 20070101

• Effect of a M1 allosteric modulator on scopolamine-induced amnesia.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20070101

• Galantamine and QTc prolongation.

  The Journal of clinical psychiatry 20070101

• Posttraumatic stress disorder-like symptoms after treatment with acetylcholinesterase inhibitors.

  The Journal of neuropsychiatry and clinical neurosciences 20070101

• Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).

  Archives of gerontology and geriatrics 20070101

• Results of galantamine treatment in acute traumatic brain injury.

  Psychosomatics 20070101

• Brain activation in elderly people with and without dementia: Influences of gender and medication.

  The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20070101

• Naturalistic treatment of Alzheimer's disease with galantamine: 12-month follow-up from the NATURE study.

  CNS drugs 20070101

• Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.

  Dementia and geriatric cognitive disorders 20070101

• Galantamine for Alzheimer's disease and mild cognitive impairment.

  Neuroepidemiology 20070101

• Galantamine effects on memory, spatial cue utilization, and neurotrophic factors in aged female rats.

  Cell transplantation 20070101

• [EEG and clinical psychophysiological study of functional changes in the chronic ischemic brain with increased acetylcholinergic activity].

  Fiziologiia cheloveka 20070101

• Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.

  PharmacoEconomics 20070101

• [Alzheimer drugs for mild cognitive impairment].

  Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater 20070101

• [Criminal clozapine intoxications].

  Anesteziologiia i reanimatologiia 20070101

• Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).

  Drug safety 20070101

• Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.

  Current medicinal chemistry 20070101

• Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.

  Journal of neural transmission. Supplementum 20070101

• Alkaloid variability in Leucojum aestivum from wild populations.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20070101

• [Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20070101

• In vitro galantamine-memantine co-application: mechanism of beneficial action.

  Neuropharmacology 20061201

• The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor.

  British journal of pharmacology 20061201

• Biomimetic synthesis of (+/-)-galanthamine and asymmetric synthesis of (-)-galanthamine using remote asymmetric induction.

  Chemical & pharmaceutical bulletin 20061201

• Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues.

  Neuro endocrinology letters 20061201

• Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial.

  International journal of clinical pharmacology and therapeutics 20061201

• 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.

  Bioorganic & medicinal chemistry letters 20061115

• Micellar electrokinetic chromatography-electrospray ionization mass spectrometry for the identification of drug impurities.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061107

• Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity.

  European journal of pharmacology 20061107

• Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.

  Journal of psychiatry & neuroscience : JPN 20061101

• Blockade of Ca2+ -activated K+ channels by galantamine can also contribute to the potentiation of catecholamine secretion from chromaffin cells.

  European journal of pharmacology 20061024

• Augmentation of near infrared diffuse reflectance and transmittance spectral data for the development of robust PLSBC models for classifying double blind clinical trial tablets.

  Journal of pharmaceutical and biomedical analysis 20061011

• [Medical treatment of Alzheimer's disease].

  Ugeskrift for laeger 20061002

• [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].

  Revista de neurologia 20061001

• Use of antidementia agents in vascular dementia: beyond Alzheimer disease.

  Mayo Clinic proceedings 20061001

• A prospective, open-label trial of galantamine in autistic disorder.

  Journal of child and adolescent psychopharmacology 20061001

• Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

  Biological psychiatry 20060915

• Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment.

  Toxicology in vitro : an international journal published in association with BIBRA 20060901

• Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators.

  The Journal of pharmacology and experimental therapeutics 20060901

• [Risperidone and cerebrovascular adverse effects in elderly patients with dementia].

  Revista clinica espanola 20060901

• Harmless herbs? Think again: merits of a complete medication history.

  Journal of the American Medical Directors Association 20060901

• Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval.

  Pharmacology, biochemistry, and behavior 20060901

• Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana.

  Journal of natural products 20060901

• Adjuvant galantamine for cognitive dysfunction in a patient with bipolar disorder.

  Journal of psychiatric practice 20060901

• Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents.

  Proceedings of the National Academy of Sciences of the United States of America 20060829

• [Advances in Alzheimer's disease treatment].

  La Revue de medecine interne 20060801

• [Cholinesterase inhibitor therapy in long term care settings].

  La Revue de medecine interne 20060801

• [Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20060801

• Alzheimer's disease.

  Lancet (London, England) 20060729

• [Mortality-associated factors in patients with Alzheimer's disease treated with galantamine].

  Medicina clinica 20060708

• Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?

  Schizophrenia research 20060701

• Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.

  Age and ageing 20060701

• Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.

  Journal of clinical pharmacology 20060701

• Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.

  Journal of clinical pharmacology 20060701

• Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20060701

• Choline pivaloyl ester strengthened the benefit effects of Tacrine and Galantamine on electroencephalographic and cognitive performances in nucleus basalis magnocellularis-lesioned and aged rats.

  Pharmacology, biochemistry, and behavior 20060701

• Effects of galantamine and donepezil on active and passive avoidance tests in rats with induced hypoxia.

  Journal of pharmacological sciences 20060701

• Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery.

  Journal of pharmaceutical sciences 20060601

• Alzheimer's disease: beware of interactions with cholinesterase inhibitors.

  Prescrire international 20060601

• Once-daily formulation of galantamine.

  Journal of the American Medical Directors Association 20060601

• [Pharmacotherapy of a patient with Alzheimer's disease: interactions with the antidementive galantamine].

  Medizinische Monatsschrift fur Pharmazeuten 20060601

• Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.

  The American journal of geriatric pharmacotherapy 20060601

• [Anti-dementia drugs for dementia syndromes--just unkept promises?].

  MMW Fortschritte der Medizin 20060515

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.

  International journal of clinical practice 20060501

• [Complete atrioventricular block during galantamine therapy].

  Nederlands tijdschrift voor geneeskunde 20060429

• Total synthesis of (+/-)-galanthamine.

  Organic letters 20060427

• An innovative approach to involve patients in measuring treatment effects in drug trials.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060411

• Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060411

• Clinical trials in mild cognitive impairment: lessons for the future.

  Journal of neurology, neurosurgery, and psychiatry 20060401

• Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice.

  The Journal of pharmacology and experimental therapeutics 20060401

• Accurate product ion mass spectra of galanthamine derivatives.

  Journal of mass spectrometry : JMS 20060401

• Galantamine treatment of cognitive impairment in bipolar disorder: four cases.

  Bipolar disorders 20060401

• A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study.

  Journal of clinical psychopharmacology 20060401

• Antiamnesic effect of combined treatment with galantamine and estradiol in middle-aged ovariectomized female rats.

  Bulletin of experimental biology and medicine 20060401

• [Complete atrioventricular block during galantamine therapy].

  Nederlands tijdschrift voor geneeskunde 20060311

• Galantamine may improve attention and speech in schizophrenia.

  Human psychopharmacology 20060301

• Time window in cholinomimetic ability to rescue long-term potentiation in neurodegenerating anti-nerve growth factor mice.

  Journal of Alzheimer's disease : JAD 20060301

• Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.

  Clinical therapeutics 20060301

• Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats.

  The Journal of pharmacology and experimental therapeutics 20060201

• Galantamine for Alzheimer's disease and mild cognitive impairment.

  The Cochrane database of systematic reviews 20060125

• Galantamine for vascular cognitive impairment.

  The Cochrane database of systematic reviews 20060125

• Cholinesterase inhibitors for Alzheimer's disease.

  The Cochrane database of systematic reviews 20060125

• Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20060101

• Galantamine increases excitability of CA1 hippocampal pyramidal neurons.

  Neuroscience 20060101

• Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.

  Brain : a journal of neurology 20060101

• Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20060101

• Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis.

  Neurobiology of aging 20060101

• A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.

  International journal of geriatric psychiatry 20060101

• Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial.

  Psychopharmacology 20060101

• Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs.

  International journal of geriatric psychiatry 20060101

• Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.

  Expert opinion on investigational drugs 20060101

• Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy.

  Dementia and geriatric cognitive disorders 20060101

• Synthesis and pharmacology of galantamine.

  Chemical reviews 20060101

• Preventing protein secretion with chemical glue.

  Nature chemical biology 20060101

• The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

  Health technology assessment (Winchester, England) 20060101

• Galantamine-induced QTc prolongation.

  The Journal of clinical psychiatry 20060101

• Pharmacological and molecular enhancement of learning in aging and Alzheimer's disease.

  Journal of physiology, Paris 20060101

• [Use of reminyl (galantamine) in the treatment of dementia].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20060101

• Neuroprotection in vascular dementia.

  Cerebrovascular diseases (Basel, Switzerland) 20060101

• Current and emerging pharmacological treatment options for dementia.

  Behavioural neurology 20060101

• [Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease].

  Neurologia (Barcelona, Spain) 20060101

• Galantamine extended release.

  CNS drugs 20060101

• Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.

  Drugs & aging 20060101

• [Optimizing effect of the combined administration of 8-OH-DPAT and galantamine on depression--anxiety behavior in old rats with dementia of Alzheimer's type].

  Eksperimental'naia i klinicheskaia farmakologiia 20060101

• Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation.

  Current medicinal chemistry 20060101

• [Pharmacotherapy for Alzheimer's disease].

  Tijdschrift voor psychiatrie 20060101

• Kinetics of 13 new cholinesterase inhibitors.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20060101

• Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.

  The Journal of international medical research 20060101

• A naturalistic study of galantamine for Alzheimer's disease.

  CNS drugs 20060101

• Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes.

  Rapid communications in mass spectrometry : RCM 20060101

• Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients.

  Drug safety 20060101

• Realistic expectations for treatment success in Alzheimer's disease.

  The journal of nutrition, health & aging 20060101

• Galantamine extended release in Alzheimer's disease: profile report.

  Drugs & aging 20060101

• Alzheimer disease and its management: a review.

  American journal of therapeutics 20060101

• The N-butylcarbamate derivative of galantamine acts as an allosteric potentiating ligand on alpha7 nicotinic receptors in hippocampal neurons: clinical implications for treatment of Alzheimer's disease.

  Journal of molecular neuroscience : MN 20060101

• Galanthamine, a natural product for the treatment of Alzheimer's disease.

  Recent patents on CNS drug discovery 20060101

• Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons.

  European journal of pharmacology 20051219

• Age-related deficits in the retention of memories for cued fear conditioning are reversed by galantamine treatment.

  Behavioural brain research 20051207

• Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells.

  Neuroscience letters 20051202

• Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20051201

• Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.

  The Journal of pharmacology and experimental therapeutics 20051201

• A case with cholinesterase inhibitor responsive asymmetric posterior cortical atrophy.

  Clinical neurology and neurosurgery 20051201

• Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A.

  Journal of natural products 20051201

• Galantamine antiacetylcholinesterase activity in rat brain influenced by L-carnitine.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20051201

• Dementia.

  Clinical evidence 20051201

• Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors.

  Brain research 20051109

• Behavioral and neuropsychiatric outcomes in Alzheimer's disease.

  CNS spectrums 20051101

• A case report of paranoid delusion with galantamine use.

  Journal of the American Geriatrics Society 20051101

• Divergent enantioselective synthesis of (-)-galanthamine and (-)-morphine.

  Journal of the American Chemical Society 20051026

• Reduction of voluntary ethanol consumption in alcohol-preferring Alko alcohol (AA) rats by desoxypeganine and galanthamine.

  European journal of pharmacology 20051017

• Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury.

  Journal of clinical psychopharmacology 20051001

• Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

  Journal of neurology, neurosurgery, and psychiatry 20051001

• Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers.

  Current medical research and opinion 20051001

• New anti-Alzheimer drugs from biodiversity: the role of the natural acetylcholinesterase inhibitors.

  Mini reviews in medicinal chemistry 20051001

• UK government guidance on Alzheimer's drugs postponed.

  Drug discovery today 20050901

• Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.

  Current medical research and opinion 20050901

• [Traditional dementia concepts in transition--must we change our views?].

  Der Nervenarzt 20050901

• Galantamine-induced behavioral recovery after sublethal excitotoxic lesions to the rat medial septum.

  Behavioural brain research 20050830

• Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

  BMJ (Clinical research ed.) 20050806

• Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells.

  British journal of pharmacology 20050801

• Development of a novel high-concentration galantamine formulation suitable for intranasal delivery.

  Journal of pharmaceutical sciences 20050801

• Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.

  British journal of pharmacology 20050701

• A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.

  European journal of clinical pharmacology 20050701

• Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.

  International journal of clinical practice 20050701

• [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].

  Tijdschrift voor gerontologie en geriatrie 20050701

• Predicting drug metabolism--an evaluation of the expert system METEOR.

  Chemistry & biodiversity 20050701

• Acute effects of physostigmine and galantamine on the binding of [18F]fluoro-A-85380: a PET study in monkeys.

  Synapse (New York, N.Y.) 20050615

• Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.

  Psychopharmacology 20050601

• Reduction of caregiver burden in Alzheimer's disease by treatment with galantamine.

  CNS spectrums 20050601

• Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20050601

• [Changing the anticholinesterase in Alzheimer's disease].

  Revista de neurologia 20050601

• Galantamine: excess mortality.

  Prescrire international 20050601

• Stimulation of nicotinic acetylcholine receptors protects motor neurons.

  Biochemical and biophysical research communications 20050520

• Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects.

  Journal of clinical pharmacology 20050501

• Switching from donepezil to galantamine: a double-blind study of two wash-out periods.

  International journal of geriatric psychiatry 20050501

• Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.

  Archives of neurology 20050501

• A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.

  Human psychopharmacology 20050401

• Capillary electrophoresis-mass spectrometry in impurity profiling of pharmaceutical products.

  Electrophoresis 20050401

• [Cost-effectiveness of galantamine in a german context].

  Psychiatrische Praxis 20050401

• Actions of tacrine and galanthamine on histamine-N-methyltransferase.

  Methods and findings in experimental and clinical pharmacology 20050401

• Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation.

  Current medical research and opinion 20050401

• [Determination of galanthamine in bulb of Lycoris radiata by RP-HPLC].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20050401

• Cholinesterase inhibitors in the treatment of dementia.

  The Journal of the American Osteopathic Association 20050301

• Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.

  Journal of the American Academy of Nurse Practitioners 20050301

• Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050223

• Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism.

  European journal of pharmacology 20050221

• Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits.

  Brain research 20050208

• Regulatory authorities review use of galantamine in mild cognitive impairment.

  BMJ (Clinical research ed.) 20050205

• Butyrylcholinesterase inhibitory guaianolides from Amberboa ramosa.

  Archives of pharmacal research 20050201

• Indicators of neuroprotection with galantamine.

  Brain research bulletin 20050130

• Effect of cholinergic medication, before and after focal photothrombotic ischemic cortical injury, on histological and functional outcome in aged and young adult rats.

  Behavioural brain research 20050106

• Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients.

  Progress in neuro-psychopharmacology & biological psychiatry 20050101

• Not all head-to-head trials are created equal: results from an open-label, short-term study seem inconsistent with previous donepezil literature.

  International journal of geriatric psychiatry 20050101

• Look-alike, sound-alike drug errors with Reminyl and Amaryl.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050101

• Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.

  Dementia and geriatric cognitive disorders 20050101

• [Treatment of dementia].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050101

• Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20050101

• The effect of galantamine added to clozapine on cognition of five patients with schizophrenia.

  Clinical neuropharmacology 20050101

• Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20050101

• Drug therapy of dementia in elderly patients. A review.

  Nordic journal of psychiatry 20050101

• Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study.

  American journal of Alzheimer's disease and other dementias 20050101

• [Reminyl efficacy in dementia with Levi bodies].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101

• Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study.

  Alzheimer disease and associated disorders 20050101

• Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies.

  The Journal of neuropsychiatry and clinical neurosciences 20050101

• [Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia].

  Revista espanola de salud publica 20050101

• Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity.

  Biochemical and biophysical research communications 20041217

• The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design.

  Journal of the American Chemical Society 20041201

• Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study.

  NeuroImage 20041201

• Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient.

  The Journal of clinical psychiatry 20041201

• Improved production of galanthamine and related alkaloids by methyl jasmonate in Narcissus confusus shoot-clumps.

  Planta medica 20041201

• Dementia.

  Clinical evidence 20041201

• Galantamine blocks cloned Kv2.1, but not Kv1.5 potassium channels.

  Brain research. Molecular brain research 20041124

• Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.

  Journal of the neurological sciences 20041115

• Switching from donepezil or rivastigmine to galantamine in clinical practice.

  Journal of the American Geriatrics Society 20041101

• Mechanisms of action of cognitive enhancers on neuroreceptors.

  Biological & pharmaceutical bulletin 20041101

• Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.

  European journal of neurology 20041101

• An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.

  Current medical research and opinion 20041101

• Effects of galantamine in patients with mild Alzheimer's disease.

  Current medical research and opinion 20041101

• Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.

  European journal of pharmacology 20041025

• Galantamine for Alzheimer's disease.

  The Cochrane database of systematic reviews 20041018

• Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia.

  Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20041001

• Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.

  Movement disorders : official journal of the Movement Disorder Society 20041001

• A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.

  Clinical therapeutics 20041001

• In vivo and in vitro study of the influence of the anticholinesterase drug galantamine on motor and evacuative functions of rat gastrointestinal tract.

  European journal of pharmacology 20040913

• Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial.

  JAMA 20040908

• Pharmacotherapy of chronic fatigue syndrome: another gallant attempt.

  JAMA 20040908

• Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons.

  The Journal of pharmacology and experimental therapeutics 20040901

• Evidence-based pharmacotherapy of Alzheimer's disease.

  The international journal of neuropsychopharmacology 20040901

• Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release.

  Molecular pharmacology 20040901

• Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons.

  Molecular pharmacology 20040901

• The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.

  Expert opinion on drug safety 20040901

• Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase.

  Neuropharmacology 20040901

• Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120.

  Brain research bulletin 20040830

• [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].

  Revista de neurologia 20040801

• Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation.

  Neuroscience letters 20040722

• A case study in the treatment of dementia with Lewy bodies.

  Acta psychiatrica Scandinavica 20040701

• Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease.

  Journal of the American Geriatrics Society 20040701

• Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.

  CNS spectrums 20040701

• [Galantamine, an acetylcholinesterase inhibitor with various actions].

  Medizinische Monatsschrift fur Pharmazeuten 20040701

• Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats.

  The Journal of pharmacology and experimental therapeutics 20040601

• Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge.

  Journal of ethnopharmacology 20040601

• Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.

  Current medical research and opinion 20040601

• Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.

  International journal of geriatric psychiatry 20040601

• Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01).

  Arquivos de neuro-psiquiatria 20040601

• ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study.

  Collegium antropologicum 20040601

• Dementia.

  Clinical evidence 20040601

• Total synthesis of (-)-galanthamine by remote asymmetric induction.

  Angewandte Chemie (International ed. in English) 20040510

• The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease.

  CNS spectrums 20040501

• Drug therapy for Alzheimer's disease.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20040427

• Emerging therapies for vascular dementia and vascular cognitive impairment.

  Stroke 20040401

• Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease.

  Current medical research and opinion 20040401

• Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.

  The American journal of psychiatry 20040301

• Galantamine: use in Alzheimer's disease and related disorders.

  Expert review of neurotherapeutics 20040301

• The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.

  Archives of neurology 20040201

• A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease.

  International journal of clinical practice 20040201

• Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.

  Dementia and geriatric cognitive disorders 20040101

• Potentiation effects of (+/-)huprine X, a new acetylcholinesterase inhibitor, on nicotinic receptors in rat cortical synaptosomes.

  Neuropharmacology 20040101

• Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors.

  Neuropharmacology 20040101

• Pharmacologic treatment expectations in the management of dementia with Lewy bodies.

  Dementia and geriatric cognitive disorders 20040101

• Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis.

  Dementia and geriatric cognitive disorders 20040101

• A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.

  International journal of geriatric psychiatry 20040101

• Galantamine facilitates acquisition of hippocampus-dependent trace eyeblink conditioning in aged rabbits.

  Learning & memory (Cold Spring Harbor, N.Y.) 20040101

• Galantamine facilitates acquisition of a trace-conditioned eyeblink response in healthy, young rabbits.

  Learning & memory (Cold Spring Harbor, N.Y.) 20040101

• Acetylcholinesterase inhibition in Alzheimer's Disease.

  Current pharmaceutical design 20040101

• Pharmacokinetics and tissue distribution of galantamine and galantamine-related radioactivity after single intravenous and oral administration in the rat.

  Arzneimittel-Forschung 20040101

• Treatment of Huntington's disease with galantamine.

  International clinical psychopharmacology 20040101

• Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

  Drugs & aging 20040101

• [Drug therapy for aged patients with Alzheimer disease].

  Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20040101

• [The virtual synapse what is its contribution to understanding cholinergic neural transmission?].

  Therapie 20040101

• Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a 'real world' study.

  Archives of gerontology and geriatrics. Supplement 20040101

• What are the treatment options for patients with severe Alzheimer's disease?

  CNS drugs 20040101

• The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?

  Journal of the American Medical Directors Association 20040101

• Wernicke-Korsakoff syndrome and galantamine.

  Psychosomatics 20040101

• Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.

  Dementia and geriatric cognitive disorders 20040101

• Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20040101

• Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors.

  Alzheimer disease and associated disorders 20040101

• Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.

  Alzheimer disease and associated disorders 20040101

• The needs of the caregiver in the long-term treatment of Alzheimer disease.

  Alzheimer disease and associated disorders 20040101

• Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

  Drugs & aging 20040101

• Long-term outcomes of galantamine treatment in patients with Alzheimer disease.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20040101

• Alleviation of multiple abnormalities by galantamine treatment in two patients with dementia with Lewy bodies.

  American journal of Alzheimer's disease and other dementias 20040101

• Molecular recognition between 4a S/R-galanthamine diastereoisomers and alpha-cyclodextrin.

  Journal of molecular modeling 20031201

• Galanthamine distribution in Bulgarian Galanthus spp.

  Die Pharmazie 20031201

• Galanthamine pattern in Narcissus confusus plants.

  Planta medica 20031201

• A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20031201

• Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.

  Prescrire international 20031201

• The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release.

  Molecular pharmacology 20031101

• Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease.

  European journal of neurology 20031101

• Editorial comment--How to treat vascular dementia?

  Stroke 20031001

• Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.

  International journal of geriatric psychiatry 20031001

• The effects of galantamine treatment on caregiver time in Alzheimer's disease.

  International journal of geriatric psychiatry 20031001

• Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent.

  Life sciences 20030919

• (-)-9-Dehydrogalanthaminium bromide, a new cholinesterase inhibitor, enhances place and object recognition memory in young and old rats.

  Neurobiology of learning and memory 20030901

• Update on Alzheimer drugs (galantamine).

  The neurologist 20030901

• Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.

  International journal of geriatric psychiatry 20030801

• Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine.

  Sleep 20030801

• Synthesis and structure-activity relationships of open D-Ring galanthamine analogues.

  Bioorganic & medicinal chemistry letters 20030721

• [Acetylcholinesterase inhibitors].

  Revue medicale de la Suisse romande 20030701

• Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of galantamine in human heparinised plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030615

• Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

  The Journal of pharmacology and experimental therapeutics 20030601

• An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.

  Clinical therapeutics 20030601

• Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

  Clinical therapeutics 20030601

• Dementia.

  Clinical evidence 20030601

• The impact of drugs against dementia on cognition in aging and mild cognitive impairment.

  Pharmacopsychiatry 20030601

• [Current therapy of patients with dementia].

  MMW Fortschritte der Medizin 20030526

• Extended lifetime of reagentless detector for multiple inhibitors of acetylcholinesterase.

  Biosensors & bioelectronics 20030501

• Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations.

  Journal of clinical pharmacology 20030501

• Galantamine.

  The Israel Medical Association journal : IMAJ 20030501

• The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure.

  International journal of geriatric psychiatry 20030401

• Galantamine: a review of its use in Alzheimer's disease and vascular dementia.

  International journal of clinical practice 20030401

• Sequential designs for phase III clinical trials incorporating treatment selection.

  Statistics in medicine 20030315

• Galantamine hydrobromide: an agent for Alzheimer's disease.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030301

• Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats.

  Progress in neuro-psychopharmacology & biological psychiatry 20030201

• Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease.

  Stroke 20030201

• Galantamine blocks delayed rectifier, but not transient outward potassium current in rat dissociated hippocampal pyramidal neurons.

  Neuroscience letters 20030109

• Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis.

  Dementia and geriatric cognitive disorders 20030101

• Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders.

  Phytotherapy research : PTR 20030101

• Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.

  Dementia and geriatric cognitive disorders 20030101

• Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase, and nicotinic acetylcholine receptors.

  Neuroscience 20030101

• [Zoofilia as late complication of Parkinson's disease. Circe drugs and Mercury antidotes].

  Neurologia (Barcelona, Spain) 20030101

• Antioxidant properties of galantamine hydrobromide.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20030101

• A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.

  Drugs & aging 20030101

• Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species.

  Arzneimittel-Forschung 20030101

• Current treatments for Alzheimer's disease: cholinesterase inhibitors.

  The Journal of clinical psychiatry 20030101

• Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.

  CNS drugs 20030101

• Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease.

  Alzheimer disease and associated disorders 20030101

• Clinical experience of galantamine in dementia: a series of case reports.

  Current medical research and opinion 20030101

• Capillary electrophoresis as an orthogonal technique in HPLC method validation.

  Journal of capillary electrophoresis and microchip technology 20030101

• [Mechanisms of action of Alzheimer medications].

  Duodecim; laaketieteellinen aikakauskirja 20030101

• Galantamine vs donepezil in the treatment of Alzheimer's disease.

  Drugs & aging 20030101

• Clinical pharmacokinetics of galantamine.

  Clinical pharmacokinetics 20030101

• [Galantamine (reminyl) in the treatment of Alzheimer's disease and vascular dementia].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20030101

• Galantamine in the treatment of adult autism: a report of three clinical cases.

  International journal of psychiatry in medicine 20030101

• Galantamine in the treatment of vascular dementia.

  International psychogeriatrics 20030101

• Galantamine may be effective in treating autistic disorder.

  BMJ (Clinical research ed.) 20021214

• [Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].

  Fortschritte der Medizin. Originalien 20021205

• Unconventional ligands and modulators of nicotinic receptors.

  Journal of neurobiology 20021201

• Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together.

  Journal of clinical pharmacology 20021201

• Treatment options: the latest evidence with galantamine (Reminyl).

  Journal of the neurological sciences 20021115

• The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease.

  Journal of the neurological sciences 20021115

• Use of galantamine to treat vascular dementia.

  Lancet (London, England) 20021109

• Use of galantamine to treat vascular dementia.

  Lancet (London, England) 20021109

• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.

  Current neurology and neuroscience reports 20021101

• A novel treatment for patients with Alzheimer's disease and with vascular dementia.

  Annals of the New York Academy of Sciences 20021101

• Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease treated with galantamine.

  Annals of the New York Academy of Sciences 20021101

• [Anti-dementia drugs for Alzheimer disease in present and future].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20021101

• A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat.

  European journal of pharmacology 20021025

• Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts.

  Life sciences 20021011

• The impact of journal advertisements on prescribers of cholinesterase inhibitors.

  International journal of geriatric psychiatry 20021001

• [Galantamine: a novel cholinergic agent for Alzheimer's disease].

  Neurologia (Barcelona, Spain) 20021001

• [The role of substantia nigra in the cognitive activity in cats].

  Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova 20021001

• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.

  Current neurology and neuroscience reports 20020901

• Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects.

  Journal of clinical pharmacology 20020901

• Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine.

  European journal of neurology 20020901

• Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months.

  International journal of clinical practice 20020901

• Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20020901

• An efficient enantioselective synthesis of (-)-galanthamine.

  Angewandte Chemie (International ed. in English) 20020802

• Galantamine for vascular dementia.

  The Lancet. Neurology 20020801

• Galantamine for treatment-resistant schizophrenia.

  The American journal of psychiatry 20020701

• Medical treatment of Alzheimer's disease: past, present, and future.

  Medicine and health, Rhode Island 20020701

• [Nicotinic Receptor, galantamine and Alzheimer disease].

  Revista de neurologia 20020601

• The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.

  International journal of clinical practice. Supplement 20020601

• The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

  International journal of clinical practice. Supplement 20020601

• Galanthamine as bis-functional ligand for the acetylcholinesterase.

  Journal of molecular modeling 20020601

• [Latest therapies for treating dementia].

  Atencion primaria 20020515

• The metabolism and excretion of galantamine in rats, dogs, and humans.

  Drug metabolism and disposition: the biological fate of chemicals 20020501

• The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.

  Molecular pharmacology 20020501

• Galantamine for vascular dementia: some answers, some questions.

  Lancet (London, England) 20020413

• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.

  Lancet (London, England) 20020413

• Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.

  Journal of clinical pharmacology 20020401

• Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.

  Current medical research and opinion 20020101

• Galantamine for Alzheimer's disease.

  The Cochrane database of systematic reviews 20020101

• Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.

  PharmacoEconomics 20020101

• Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.

  Dementia and geriatric cognitive disorders 20020101

• [New theory! Galantamine and nicotinic-cholinergic transmission].

  Pharmazie in unserer Zeit 20020101

• Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.

  CNS drug reviews 20020101

• New drugs 2002, part 1.

  Nursing 20020101

• Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.

  PharmacoEconomics 20020101

• Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

  International journal of technology assessment in health care 20020101

• Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.

  Clinical neuropharmacology 20020101

• Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy.

  Journal of neural transmission. Supplementum 20020101

• Nicotinic cholinergic modulation: galantamine as a prototype.

  CNS drug reviews 20020101

• Vascular dementia: galantamine (Reminyl) as an emerging therapeutic option.

  Acta neurologica Scandinavica. Supplementum 20020101

• Cognitive decline and treatment options for patients with vascular dementia.

  Acta neurologica Scandinavica. Supplementum 20020101

• Non-cognitive benefits of galantamine (Reminyl) treatment in vascular dementia.

  Acta neurologica Scandinavica. Supplementum 20020101

• Solid-phase extraction and reversed-phase high-performance liquid chromatography of the five major alkaloids in Narcissus confusus.

  Phytochemical analysis : PCA 20020101

• A clinical overview of cholinesterase inhibitors in Alzheimer's disease.

  International psychogeriatrics 20020101

• [Acetylcholinesterase inhibitors--beyond Alzheimer's disease].

  Psychiatria polska 20020101

• [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].

  MMW Fortschritte der Medizin 20011213

• Unsafe prescription medication switching recommendations.

  Clinical therapeutics 20011201

• Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.

  Prescrire international 20011201

• Current status and new developments with galantamine in the treatment of Alzheimer's disease.

  Expert opinion on pharmacotherapy 20011201

• [Perspectives for drug treatment in Alzheimer's disease].

  Annales de medecine interne 20011201

• Galantamine hydrobromide.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20011115

• Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

  Journal of neurology, neurosurgery, and psychiatry 20011101

• Galantamine: a new alzheimer drug with a past life.

  The Annals of pharmacotherapy 20011101

• Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada.

  Neurology 20010925

• Sleep and the cholinergic rapid eye movement sleep induction test in patients with primary alcohol dependence.

  Biological psychiatry 20010901

• Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease.

  International journal of geriatric psychiatry 20010901

• [Anticholinesterase agents in Alzheimer's disease].

  Revue medicale de Bruxelles 20010901

• Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease.

  Alzheimer disease and associated disorders 20010801

• Maintaining cognitive function in Alzheimer disease: how effective are current treatments?

  Alzheimer disease and associated disorders 20010801

• Maintaining functional and behavioral abilities in Alzheimer disease.

  Alzheimer disease and associated disorders 20010801

• Use of biomimetic diversity-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product.

  Journal of the American Chemical Society 20010711

• Use of cholinesterase inhibitors for treatment of Alzheimer disease.

  Cleveland Clinic journal of medicine 20010701

• Featured CME topic: dementia. Medication update.

  Southern medical journal 20010701

• Galantamine (reminyl) for Alzheimer's disease.

  The Medical letter on drugs and therapeutics 20010625

• Meeting the challenges of vascular dementia. Introduction.

  International journal of clinical practice. Supplement 20010501

• The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).

  International journal of clinical practice. Supplement 20010501

• FDA approves galantamine for Alzheimer's disease.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010415

• Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.

  Neuroscience letters 20010316

• Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning.

  Proceedings of the National Academy of Sciences of the United States of America 20010213

• Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs.

  Proteins 20010201

• Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.

  Biological psychiatry 20010201

• Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease.

  Biological psychiatry 20010201

• APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.

  Dementia and geriatric cognitive disorders 20010101

• Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

  Health technology assessment (Winchester, England) 20010101

• Galantamine for Alzheimer's disease.

  The Cochrane database of systematic reviews 20010101

• Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Introduction.

  Clinical therapeutics 20010101

• Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine.

  Clinical therapeutics 20010101

• Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials.

  Clinical therapeutics 20010101

• Switching previous therapies for Alzheimer's disease to galantamine.

  Clinical therapeutics 20010101

• Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers.

  Clinical therapeutics 20010101

• Pharmacokinetic rationale for switching from donepezil to galantamine.

  Clinical therapeutics 20010101

• Galantamine introduced in Europe.

  American journal of Alzheimer's disease and other dementias 20010101

• Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking.

  Journal of molecular graphics & modelling 20010101

• Newest developments in dementia treatment and prevention.

  Geriatric nursing (New York, N.Y.) 20010101

• Galantamine for Alzheimer's disease.

  The Cochrane database of systematic reviews 20010101

• Drugs used for cognitive symptoms of Alzheimer's disease.

  Perspectives in psychiatric care 20010101

• Galantamine: a review of its use in Alzheimer's disease.

  Drugs 20001101

• Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution.

  FEBS letters 19991217

• Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats.

  Psychopharmacology 19920101

• Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).

  Der Anaesthesist 19771201